Addendum

Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66

Status
Status: Commission completed
Project no.
A23-106
Last updated

Report documents

  1. Addendum

    Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66

    published on
    Document type
    PDF document, 561 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-106

Dossier assessment

Indication:

Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy

Result of dossier assessment:
  • If high-dose therapy is an option: Unchanged after addendum: added benefit not proven
  • If high-dose therapy is not an option: Unchanged after addendum: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2023-12-21 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-106
Commission
Commission awarded on 08.11.2023 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://dx.doi.org/10.60584/A23-106

Connected Projects

  1. Dossier assessment

    Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-66
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form